Esperion Logo (primary).png
Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
March 26, 2024 08:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., March 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the 23rd Annual Needham Virtual Healthcare Conference. Sheldon Koenig, President and...
Esperion Logo (primary).png
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
March 25, 2024 16:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., March 25, 2024 (GLOBE NEWSWIRE) --  Esperion (NASDAQ: ESPR) today announced the acceptance of three CLEAR (Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen)...
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
March 22, 2024 15:10 ET | Esperion Therapeutics, Inc.
– New Labels Expand Treatable Population to ~70 Million Patients in U.S. – – First LDL-C Lowering Non-Statin Indicated for Primary Prevention Patients – – Approvals Based on Positive CLEAR Outcomes...
Esperion Logo (primary).png
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
March 22, 2024 11:04 ET | Esperion Therapeutics, Inc.
– Positive CHMP Opinions Are Based On The Analyses Of The Phase 3 Of The CLEAR (Cholesterol Lowering via Bempedoic Acid, an ATP Citrate Lyase (ACL)-Inhibiting Regimen) Outcomes Trial1 – – European...
Esperion Logo (primary).png
Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024 06:00 ET | Esperion Therapeutics, Inc.
– FY23 U.S. Net Product Revenue Grew 40% Y/Y to $78.3 Million; FY23 Total Revenue Grew 54% Y/Y to $116.3 Million – – Q4 U.S. Net Product Revenue Grew 39% Y/Y to $20.8 Million; Q4 Total Revenue Grew...
Esperion Logo (primary).png
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 16, 2024 16:30 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on February 13, 2024, the Company granted 66 new employees 204,900 restricted stock units (RSUs)...
Esperion Logo (primary).png
Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27
February 13, 2024 08:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2023 financial results before the market opens on Tuesday,...
Esperion Logo (primary).png
RFK, Esperion Therapeutics Announce 2024 Promotional Schedule
February 01, 2024 14:00 ET | Esperion Therapeutics, Inc.
CONCORD, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- RFK Racing and Esperion Therapeutics have announced the promotional schedule for the 2024 season, highlighted by a four-race slate, and numerous...
Esperion Logo (primary).png
Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
January 23, 2024 16:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”, “we”, “us” or “our”) (Nasdaq: ESPR) announced today the closing of its previously announced underwritten...
Esperion Logo (primary).png
Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock
January 18, 2024 21:15 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”, “we”, “us” or “our”) (Nasdaq: ESPR) announced today the pricing of its previously announced underwritten...